Blerina Resuli
A5091618699- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Chromatin Remodeling and Cancer
- Computational Drug Discovery Methods
- Cancer Mechanisms and Therapy
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Mechanisms of cancer metastasis
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- PI3K/AKT/mTOR signaling in cancer
- Enzyme function and inhibition
- Brain Metastases and Treatment
- Peptidase Inhibition and Analysis
- Ovarian cancer diagnosis and treatment
- Synthesis and biological activity
- Acute Myeloid Leukemia Research
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
German Center for Lung Research
2024-2025
LMU Klinikum
2023-2025
Ludwig-Maximilians-Universität München
2023-2025
München Klinik
2024
Istituti Fisioterapici Ospitalieri
2023
Fondazione IRCCS Istituto Nazionale dei Tumori
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2023
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis 424 patients with non-small cell lung cancer (NSCLC), we identified and validated coalterations KEAP1, SMARCA4, CDKN2A as major independent determinants inferior clinical outcomes KRASG12Ci monotherapy. Collectively, comutations these three tumor suppressor genes segregated into distinct prognostic subgroups captured ∼50% those early...
Evaluating patients and treatment decisions in a multidisciplinary tumor board has led to better quality of care longer survival cancer patients. The aim this study was evaluate recommendations for thoracic oncology regarding guideline adherence transferal into clinical practice.We evaluated the at Ludwig-Maximilians University (LMU) Hospital Munich between 2014 2016. We compared patient characteristics guideline-adherent non-guideline-adherent recommendations, as well transferred...
BackgroundDocetaxel alone or in combination with ramucirumab nintedanib is recommended as second-line treatment metastatic non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy immune-checkpoint inhibitors (ICI). The purpose of our study was to compare the toxicity profile and efficacy docetaxel paclitaxel- pemetrexed-platinum ICI.Patients und MethodsMetastatic NSCLC treated pemetrexed paclitaxel-platinum without ICI were included...
<title>Abstract</title> Anaplastic lymphoma kinase tyrosine inhibitors (ALK TKIs) show robust activity in patients with non-small-cell lung cancer (NSCLC) harboring an ALK-rearrangement. Rare but serious side effects, such as pneumonitis can occur ALK TKIs. We here report a case of patient NSCLC echinoderm microtubule-associated protein-like 4-anaplastic (EML4- ALK) translocation who tolerated brigatinib following alectinib-induced pneumonitis. The was notable for diffuse ground-glass...
<p>Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.</p>
<p>Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.</p>
<p>Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.</p>
<p>A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease without untreated brain metastases; B) Survival outcomes treated metastases to starting KRAS G12Ci; C) according PD-L1 status (TPS: tumor proportion score); D) survival immune checkpoint inhibitor therapy.</p>
<p>A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease without untreated brain metastases; B) Survival outcomes treated metastases to starting KRAS G12Ci; C) according PD-L1 status (TPS: tumor proportion score); D) survival immune checkpoint inhibitor therapy.</p>
<p>Survival outcomes according to KEAP1 (A), SMARCA4 (B), and CDKN2A (C) co-mutation status in Cohorts A B.</p>
<p>Survival outcomes according to KEAP1 (A), SMARCA4 (B), and CDKN2A (C) co-mutation status in Cohorts A B.</p>
<p>Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.</p>
<p>Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) B; C) further subclassifying KEAP1MUT tumors mutation status; D) PFS OS status in KSCWT the overall study cohort.</p>
<p>Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) B; C) further subclassifying KEAP1MUT tumors mutation status; D) PFS OS status in KSCWT the overall study cohort.</p>